<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561375</url>
  </required_header>
  <id_info>
    <org_study_id>20-642</org_study_id>
    <nct_id>NCT04561375</nct_id>
  </id_info>
  <brief_title>Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery</brief_title>
  <official_title>A Pilot Study Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery From Ambulatory Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      pilot study to evaluate the effect of incorporating sublingual sufentanil into our&#xD;
      perioperative opioid regimen for ambulatory orthopedic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot study to evaluate the effect of incorporating sublingual sufentanil into our&#xD;
      perioperative opioid regimen for ambulatory orthopedic surgery. The results will help us&#xD;
      estimate treatment effect and determine sample size for a subsequent full-scale clinical&#xD;
      trial.&#xD;
&#xD;
      Primary Endpoint: total amount of fentanyl consumed during hospital admission. Secondary&#xD;
      Endpoints: 1) phase I recovery time; and, 2) time to fitness for discharge.&#xD;
&#xD;
      Exploratory Endpoints 1) pain; 2) time to first request for analgesia; and, 3) incidence of&#xD;
      nausea and vomiting between the end of anesthesia and hospital discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">September 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total consumption of fentanyl</measure>
    <time_frame>3 hours</time_frame>
    <description>The total amount of fentanyl consumed after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>2 hours.</time_frame>
    <description>The pain score will be measured as 0-10 Verbal Response Scores conducted at rest. O meaning no pain, and 10 being the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting</measure>
    <time_frame>2 hours.</time_frame>
    <description>The investigator will use the (PONV) Intensity Scale, at intervals will be used, for postoperative nausea and vomiting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Knee Arthroscopy</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>30 µg tablet of sublingual sufentanil</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>50 µg fentanyl</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18-65 years;&#xD;
&#xD;
          -  Scheduled for elective knee arthroscopy without anticipated ligamentous repair;&#xD;
&#xD;
          -  Planned general anesthesia without a regional block or wound infiltration with local&#xD;
             anesthesia;&#xD;
&#xD;
          -  Planned day-of-surgery discharge.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opioid tolerance defined by ≥15 mg of oral morphine daily or equianalgesic dose of&#xD;
             another opioid within 30 days of surgery;&#xD;
&#xD;
          -  Known hypersensitivity to sufentanil or components of DSUVIA;&#xD;
&#xD;
          -  Active seizure disorder;&#xD;
&#xD;
          -  Increased intracranial pressure, brain tumor, head injury, or impaired consciousness;&#xD;
&#xD;
          -  Severe chronic pulmonary disease;&#xD;
&#xD;
          -  Severe bronchial asthma;&#xD;
&#xD;
          -  Gastrointestinal obstruction;&#xD;
&#xD;
          -  Hepatic or renal insufficiency;&#xD;
&#xD;
          -  Adrenal insufficiency;&#xD;
&#xD;
          -  Pregnancy or actively breastfeeding;&#xD;
&#xD;
          -  Serotonergic drug use within 8 weeks of surgery;&#xD;
&#xD;
          -  Active treatment with CYP34A inhibitors (e.g. erythromycin, clarithromycin,&#xD;
             ketoconazole, ritonavir, etc.) or inducers (e.g. rifampin, carbamazepine, phenytoin,&#xD;
             etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabry Ayad, MD</last_name>
    <phone>216-476-2275</phone>
    <email>Saayad@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabry Ayad, MD</last_name>
      <phone>216-476-2245</phone>
      <email>Saayad@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sabry Ayad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

